CLINICAL SIGNIFICANCE OF FACTOR V AND PROTHROMBIN GENES POLYMORPHISM
https://doi.org/10.25837/HAT.2019.63.13.004
Abstract
In the 1990s, two gene polymorphisms — factor V Leiden (FVLeiden) and prothrombin G20210A (FII G20210A) were recognized as a genetic substrate for the development of thrombophilia. Polymorphism FVLeiden is associated with the development of resistance to anticoagulant action of protein C, and polymorphism FII G20210A with a high level of prothrombin in plasma. In healthy individuals of Caucasian origin, the prevalence of FVLeiden is between 2 and 10%. In patients with venous thromboembolism, the prevalence FVLeiden is about 20%. FII G20210A is found in 1—5% of the general Caucasian population and in 4—18% of patients with venous thromboembolism. These indicators depend on the selection of patients included in the analysis. The relationship between gene polymorphisms and the development of venous thromboembolism in women during pregnancy is discussed. The high risks of venous thromboembolism have been described for women with a homozygous FVLeiden mutation. The study of the activated protein C (APC) and factor V interaction has yielded valuable insights into how perturbations in this association lead to venous thromboembolism. It is now clear that APC exerts anticoagulant effects beyond inactivating factor V by cleaving at R306 and R506, generating inactive FV. Mutation in FVLeiden abrogates this effect. In women with a heterozygous FVLeiden or heterozygous FII G20210A, the risks of venous thromboembolism are significantly low. Regardless of genetic polymorphism, a positive family history of venous thrombosis increases the risk of developing venous thromboembolism during pregnancy. The relationship between genetic polymorphism and nonthrombotic complications developing during pregnancy is discussed. Mutations of FVLeiden and FII G20210A may be associated with the risks of spontaneous abortion and repeated fetal loss.
About the Authors
A. V. Koloskov
North-Western State Medical University named after I. I. Mechnikov
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
E. V. Chernova
North-Western State Medical University named after I. I. Mechnikov
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. Virchow R. Phlogose und Thrombose im Gefäßsystem; Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Staatsdruckerei. Frankfurt. 1856.
2. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011;8:502—12. doi: 10.1038/nrcardio.2011.91
3. Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors for venous thromboembolism. Nat Rev Cardiol. 2014;11:140—56. doi: 10.1038/nrcardio.2013.211
4. Hematology: national handbook. [Gematologiya: natsional’noe rukovodstvo]. Rukovicin OA, ed. GEOTAR-Media. Moscow. 2015 (in Russian).
5. Handbook of Hematology. [Rukovodstvo po gematologii]. 2nd ed. Vorobev AI, ed. Meditsina. Moscow. 1985. V.2 (in Russian).
6. Nygaard KK, Brown GE. Essential thrombophilia: report of five cases. Arch Intern Med. 1937; 59:82—106.
7. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis. 2002;13:657—70.
8. Dahlback B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett. 2005;79:3310—6.
9. Nesheim M, Wang W, Boffa M, Nagashima J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost. 1997;78:386—91.
10. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993;90:1004—8.
11. Bertina R, Koeleman B, Koster T, Rosendaal FR, Driven RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64—7.
12. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698—703.
13. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood. 1993;82:1989—93.
14. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993;342:1503—6.
15. Svensson P, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517—22.
16. Van Cott EM, Khor B, Zehnder JL. Factor V Leiden. Am J Hematol. 2016;91:46—9. doi: 10.1002/ajh.24222
17. Vos HL. Inherited defects of coagulation factor V: the thrombotic side. J Thromb Haemost. 2006;4:35—40.
18. Asselta R, Tenchini ML, Duga S. Inherited defects of coagulation factor V: the hemorrhagic side. J Thromb Haemost. 2006;4:26—34.
19. Segers K, Dahlback B, Nicolaes GA. Coagulation factor V and thrombophilia: Background and mechanisms. Thromb Haemost. 2007;98:530—42.
20. Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992;31:3777—85.
21. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA. 1987;84:4846—50.
22. Tracy PB, Eide LL, Bowie EJ, Mann KG et al. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982;60:59—63.
23. Suehiro Y, Veljkovic DK, Fuller N, Motomura Y, Masse JM, Cramer EM et al. Endocytosis and storage of plasma factor V by human megakaryocytes. Thromb Haemost. 2005;94:585—92.
24. Greengard J, Sun X., Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet. 1994;343:1361—2.
25. Zoller B., Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994;343:1536—8.
26. De Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999; 93:1271—6.
27. Zivelin A, Mor-Cohen R, Kovalsky V, Kornbrot N, Conard J, Peyvandi F et al. Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. Blood. 2006;107:4666—8.
28. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133—4.
29. Rees DC. The population genetics of factor V Leiden (Arg506Gln). Br J Haematol. 1996;95:579—86.
30. Koloskov AV, Philippova OI, Lyshchev AA, Baturina OA, Vasileva MYu, Gulyaikhina DE et al. Frequencies of factor V (A506G), prothrombin (G20210A) and MTHFR (C677T and A1298S) polymorphisms in healthy blood donors in Saint-Petersburg. Rossiyskiy biomeditsinskiy zhurnal. 2015;16:682—9 (in Russian).
31. Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic events. Flebologiya. 2015;9:2—52 (in Russian).
32. Ekim M, Ekim H, Yılmaz YK. The prevalence of Factor V Leiden, prothrombin G20210A, MTHFR C677T and MTHFR A1298C mutations in healthy Turkish population. Hippokratia. 2015;19:309—13.
33. Emmerich J, Rosendaal F, Cattaneo M, Margaglione M, De Stefano V, Cumming T et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism — Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001;86:809—16.
34. Khor B, Van Cott EM. Laboratory evaluation of hypercoagulability. Clin Lab Med 2009;29:339—66. doi: 10.1016/j.cll.2009.03.002
35. Koloskov AV, Philippova OI. Factor V activity in women in SaintPetersburg. Tromboz gemostaz i reologiya. 2016;3:207—8 (in Russian).
36. Castoldi E, Brugge J, Nicolaes G, Girelli D, Tans G, Rosing J. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood. 2004;103:4173—9.
37. Steen M, Norstrom E, Tholander A, Bolton-Maggs PH, Mumford A, McVey JH et al. Functional characterization of factor V-Ile359Thr: A novel mutation associated with thrombosis. Blood. 2004;103:3381—7.
38. Franco R., Elion J, Tavella M, Santos SE, Zago MA. The prevalence of factor V Arg306–>Thr (factor V Cambridge) and factor V Arg306– >Gly mutations in different human populations. Thromb Haemost. 1999;81:312—3.
39. Norstrom E, Thorelli E, Dahlback B. Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood. 2002;100:524—30.
40. Butenas S, van’t Veer C, Mann KG. «Normal» thrombin generation. Blood. 1999;94:2169—78.
41. Pozzi N, Di Cera E. Prothrombin structure: unanticipated features and opportunities. Expert Rev Proteomics. 2014;11:653—5. doi: 10.1586/14789450.2014.971763
42. Haynes LM, Bouchard BA, Tracy PB, Mann KG. Prothrombin activation by platelet-associated prothrombinase proceeds through the prethrombin-2 pathway via a concerted mechanism. JBC. 2012;287:38647—55. doi: 10.1074/jbc.M112.407791
43. Tans G, Janssen-Claessen T, Hemker HC, Zwaal RF, Rosing J. Meizothrombin formation during factor Xa-catalyzed prothrombin activation. Formation in a purified system and in plasma. JBC. 1991;266:21864—73.
44. Degen SJ, Davie EW. Nucleotide sequence of the gene for human prothrombin. Biochemistry. 1987;26:6165—77.
45. Pozzi N, Chen Z, Gohara DW, Niu W, Heyduk T, Di Cera E. Crystal structure of prothrombin reveals conformational flexibility and mechanism of activation. JBC. 2013;288:22734—44. doi: 10.1074/jbc.M113.466946
46. Pozzi N, Chen Z, Pelc LA, Shropshire DB, Di Cera E. The linker connecting the two kringles plays a key role in prothrombin activation. Proc Natl Acad Sci USA. 2014;111:7630—5. doi: 10.1073/pnas.1403779111
47. Miranda-Vilela AL. Role of polymorphisms in factor V (FV Leiden), prothrombin, plasminogen activator inhibitor type-1 (PAI-1), methylenetetrahydrofolate reductase (MTHFR) and cystathionine-synthase (CBS) genes as risk factors for thrombophilias. Mini Rev. Med Chem. 2012;12:997—1006.
48. Buchanan GS, Rodgersm GM, Branch DW. The inherited thrombophilias: genetics, epidemiology, and laboratory evaluation. Best Pract Res Clin Obstet Gynaecol. 2003;17:397—411.
49. Lijfering WM, Middeldorp S, Veeger NJGM, Hamulyak K, Prins MH, Buller HR et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and Prothrombin G20210A. Circulation. 2010;121:1706—12. doi: 10.1161/CIRCULATIONAHA.109.906347
50. Bates S, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e691S-e736S. doi: 10.1378/chest.11-2300
51. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169:610—5. doi: 10.1001/archinternmed.2008.589
52. Rai R, Regan L. Recurrent miscarriage. Lancet. 2006;368:601—11. doi: 10.1016/S0140-6726(06)69204-0
53. Pritchard AM, Hendrix PW, Paidas MJ. Hereditary Thrombophilia and Recurrent Pregnancy Loss. Clin Obstet Gynecol. 2016;59:487—97. doi: 10.1097/GRF.0000000000000226
54. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2005;132:171—96. doi: 10.1111/j.1365-2141.2005.05847.x
55. Rodger MA, Betancourt MT, Clark P, Lindgvist PG, Dizon-Townson D, Said J et al. The association of factor V Leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med. 2010;7:e1000292. doi: 10.1371/journal.pmed.1000292
56. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361:901—8. doi: 10.1016/S0140-6736(03)12771-7
57. Roqueґ H, Paidas MJ, Funai EF, Kuczynski E, Lockwood CJ. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost. 2004;91:290—5. doi: 10.1160/TH-09-0596
58. Pickering W, Marriott K, Regan L. G20210A prothrombin gene mutation: prevalence in a recurrent miscarriage population. Clin Appl Thromb Hemost. 2001;7:25—8.
59. Pihusch R, Buchholz T, Lohse P, Rubsamen H, Rorenhofen N, Hasbargen U et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol. 2001;46:124—31.
60. Koloskov AV, Baturina OA, Lyshchev AA, Philippova OI, Stolitsa AA, Tselikova EV et al. Thrombotic and hemorrhagic risks for pregnant women. Rossiyskiy biomeditsinskiy zhurnal. 2013;14:880—90 (in Russian).
Review
For citations:
Koloskov A.V., Chernova E.V. CLINICAL SIGNIFICANCE OF FACTOR V AND PROTHROMBIN GENES POLYMORPHISM. Russian journal of hematology and transfusiology. 2018;63(3):250-257. (In Russ.) https://doi.org/10.25837/HAT.2019.63.13.004
Views:
3399
Email this article 
